Abstract

Background: Predictive molecular markers based on the consensus molecular classification of colorectal carcinoma are tested following expert recommendations. Specifically, they are tested when target molecular therapy is being considered for treatment. Their presence depends on biology but their frequency seems to be increased in advanced stages. Objective: We developed a study of cases of left-sided CRC in advanced clinical stages from a cohort of Mexican patients to evaluate the presence of predictive molecular markers. Method: Predictive molecular markers were analyzed, including BRAF, KRAS, NRAS and mismatch repair genes, in cases of advanced, left-sided colorectal carcinoma.